In clinical trials, Capofin Caspofungin Acetate Injection was administer intravenously to 171 pediatric patients, 18 of whom were less than three months old. These patients were enroll in pharmacokinetic studies, and the safety and efficacy of capsofin was assess in 66 and 105 of them, respectively. The majority of the patients received a 50 mg/m2 once-daily maintenance dose. Safety assessments were conduct before the study start, during the study, and 14 days after stopping study therapy.
Capofin Caspofungin Acetate Injection in India
Capofin Caspofungin Acetate Injection is an antifungal medication. Its available worldwide under the brand name Cancidas and is the first member of a new class of drugs called echinocandins. It is administer intravenously and has shown activity against fungi such as Candida and Aspergillus. It works by inhibiting the formation of b(1,3)-D-glucan in the cell walls of the affected organisms.
Capofin Caspofungin Acetate Injection is a fungicide that is approv to treat certain types of fungal infections and yeast infections. This used in pediatric and adult patients for the treatment of infections caused by Candida albicans and invasive aspergillosis. It is contraindicat in patients with known hypersensitivity or a history of histamine-mediated reactions. It may cause rash, facial swelling, or angioedema.
Capofin 70mg Injection is a commercially-available medication that is commonly prescrib for fungal infections. This medication kills the fungi that cause fungal infections and is prescrib by a healthcare professional. It is important to follow the recommended dosage. The dose of Capofin is dependent on the medical history, age, and gender of the patient.
Capofin Caspofungin Acetate Injection benefits
Capofin Caspofungin Acetate is a drug that is prescrib for various medical conditions. This medicine contains an ingredient known as caspofungin, which is an antifungal agent. It is available in the form of injection. You should tell your health care provider if you are allergic to caspofungin or any of its ingredients.
In a study, caspofungin was effective in treating infections caused by Candida. It was also find effective in treating invasive aspergillosis and esophageal candidiasis. The study was conduct on 19 nonneutropenic patients. The diagnostic criteria were similar to those used in adult studies.
In healthy adults, the blood concentration of caspofungin is similar in men and women after a single 70-mg intravenous dose. However, in women, the concentration of caspofungin in plasma was higher after thirteen 50-mg daily doses. However, the difference in pharmacokinetics between men and women is not clinically significant.
The long-term safety of capofin caspofungin acetate injection is unknown. Its bioavailability is low and it is excret in the urine. Its excretion rate is slow and the terminal half-life is 12 to 15 days. It is also not dialyzable. Therefore, no long-term studies are available.
The drug has shown no genotoxic or mutagenic effects in animal studies. In a mouse bone marrow chromosome test, caspofungin did not show genotoxic activity. Moreover, it was not carcinogenic at the clinical dose. It has no effect on fertility in male and female rats. However, it is recommend that pregnant women discuss the risks with their doctors.
Clinical studies have demonstrated that caspofungin has antifungal activity against various aspergillus species. It is also effective in the treatment of several candida infections. Its pharmacologic activities are also well document. The current evidence suggests that caspofungin acetate is useful in treating invasive aspergillosis and select candida infections. Further clinical studies will provide more information on its therapeutic potential.